Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Gynecol Obstet Fertil ; 33(7-8): 483-7, 2005.
Article in French | MEDLINE | ID: mdl-16005668

ABSTRACT

OBJECTIVES: To assess tocolysis with nifedipine in preterm labour during actual clinical practice in terms of efficacy and safety. PATIENTS AND METHODS: Retrospective observational study during two years including preterm labour between 26 and 33+6 weeks of amenorrhea. Preterm labour was defined by the presence of three or more uterine contractions in 10 minutes associated to cervical modifications diagnosed by vaginal sonography (length

Subject(s)
Nifedipine/therapeutic use , Obstetric Labor, Premature/drug therapy , Tocolysis/methods , Tocolytic Agents/therapeutic use , Adolescent , Adult , Blood Pressure/drug effects , Female , Humans , Nifedipine/adverse effects , Parity , Pregnancy , Pregnancy Outcome , Pregnancy, Multiple , Retrospective Studies , Safety , Tocolytic Agents/adverse effects , Treatment Outcome
2.
J Gynecol Obstet Biol Reprod (Paris) ; 33(5): 401-6, 2004 Sep.
Article in French | MEDLINE | ID: mdl-15480279

ABSTRACT

OBJECTIVES: Medical treatment using misoprostol has been recommended as an alternative to surgical evacuation for spontaneous miscarriages in the first trimester, in order to avoid anesthesia, a surgical operation and hospitalization. Our aim was to assess the efficacy and the safety of vaginal misoprostol in out-patient management of early miscarriages. MATERIAL AND METHODS: We conducted a prospective cohort study including patients with a spontaneous miscarriage of less than 14 weeks gestation. Exclusion criteria were hemorrhagic miscarriages, gestational sac larger than 40 mm and/or cranio-caudal length of the embryo of more than 30 mm. Our protocol used 4 intravaginal tablets (800 microg) of misoprostol on Day 1, out-patient follow-up, clinical and ultrasound reassessment on Day 2. If the intra-uterine antero-posterior diameter on ultrasound examination was greater than 15 mm (or the gestational sac persisted), a second dose of misoprostol was administered or surgical evacuation was performed (failure of medical treatment). RESULTS: One hundred two patients were included, of whom 30 had an inevitable or threatened miscarriage and 72 had a missed abortion. The success rate defined by complete expulsion of the products of conception without resorting to surgical evacuation and without short-term complications, was 78.4% (80 patients). Two patients were lost to follow-up at 48 hours. Complete expulsion occurred within 2 days in 94% of cases. There were 13 emergency consultations, including 8 for expulsion pain and five surgical evacuations (3 for hemorrhagic expulsion, 2 for hemorrhagic retention). All together, there were 15 surgical evacuations for retention of the products of conception after 1 or 2 doses of misoprostol. There was one case of endometritis (1%). Thirty-four patients were hospitalized, 22 for surgical evacuation and 12 for expulsion pain. CONCLUSION: It is possible to use misoprostol as a single vaginal dose (800 microg) as out-patient treatment, since it gives satisfactory efficacy (80%) and is sufficiently safe (5% needing emergency surgery). However, out-patient management should only be performed after explaining the treatment and its risks clearly to the patient.


Subject(s)
Abortion, Spontaneous/drug therapy , Misoprostol/therapeutic use , Administration, Intravaginal , Ambulatory Care , Cohort Studies , Female , Humans , Misoprostol/administration & dosage , Pregnancy , Pregnancy Trimester, First , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...